Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support... see more

NDAQ:AUPH - Post Discussion

View:
Post by jboom70 on Oct 22, 2021 4:27pm

Buyout?

We will see the price.
Comment by jboom70 on Oct 25, 2021 8:42am
No one here? I see $45-$50 buyout but hope for a staight share for share with Bristol as they have pulled back. Thoughts?
Comment by TimeScape on Oct 26, 2021 12:51am
The AUPH stock price was $22 before the rumour came out on Friday.  A 50% premium would get get it to $33.  I doubt an offer would be for much more than that.  Maybe $35.  AUPH hasn't got much of a pipeline.  The lupus nephritis indication is excellent, and they should get a big market share, but it's not a huge market.
Comment by jboom70 on Oct 26, 2021 5:10am
Current Sp was heavily manipulated by short sellers. Treatment is est @ $62000 yr but Ive also seen $90000as a price. Gets big fast with decent market penetration, say 30% of 300,000 and that's just one yr. Plus you have lic in other countries. A large Pharm Co. could also push more Ins. Co's acceptance.
Comment by TimeScape on Oct 26, 2021 6:37pm
RBC upped their target price from $23 to $34 US today. I'd be pretty happy with that price on a takeover.
Comment by ZoranSto on Oct 28, 2021 10:21am
Yes that would be great :-)
Comment by jboom70 on Oct 29, 2021 1:40am
Now talk of multiple biders @ +$40
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities